Prevenar 13 Gains China OK But Challenges Remain
In a step that may boost flagging global sales, Pfizer’s big-selling pneumococcal vaccine Prevenar 13 has finally been approved in China, but the US giant still faces more than regulatory hurdles to get the product out into the market and accessible to patients.
You may also be interested in...
After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.